These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 20682367

  • 1. The evolving role of bone-conserving therapy in patients with breast cancer.
    Brufsky AM.
    Semin Oncol; 2010 Jun; 37 Suppl 1():S12-9. PubMed ID: 20682367
    [Abstract] [Full Text] [Related]

  • 2. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ, Kaura S.
    J Med Econ; 2012 Jun; 15(1):175-84. PubMed ID: 22017235
    [Abstract] [Full Text] [Related]

  • 3. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
    Lipton A.
    Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonates as anticancer therapy for early breast cancer.
    Mahtani R, Jahanzeb M.
    Clin Breast Cancer; 2010 Oct 01; 10(5):359-66. PubMed ID: 20920980
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE.
    J Clin Oncol; 2006 Oct 20; 24(30):4895-900. PubMed ID: 17001071
    [Abstract] [Full Text] [Related]

  • 6. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
    Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann S, Steger G, Marth C, Samonigg H, Hüttner K, Fohler H, Ruecklinger E, Jakesz R, Greil R, Austrian Breast and Colorectal Cancer Study Group.
    Clin Breast Cancer; 2009 Jun 20; 9 Suppl 1():S18-27. PubMed ID: 19561003
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The use of bisphosphonates in cancer patients.
    Wu S, Dahut WL, Gulley JL.
    Acta Oncol; 2007 Jun 20; 46(5):581-91. PubMed ID: 17562434
    [Abstract] [Full Text] [Related]

  • 11. Moving into the future: treatment of bone metastases and beyond.
    Hortobagyi GN.
    Cancer Treat Rev; 2005 Jun 20; 31 Suppl 3():9-18. PubMed ID: 16249057
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
    Costa L.
    Breast; 2007 Dec 20; 16 Suppl 3():S16-20. PubMed ID: 18032044
    [Abstract] [Full Text] [Related]

  • 13. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
    Saad F, Abrahamsson PA, Miller K.
    BJU Int; 2009 Dec 20; 104(11):1573-9. PubMed ID: 20053188
    [Abstract] [Full Text] [Related]

  • 14. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
    Gnant M.
    Breast Dis; 2011 Dec 20; 33(2):71-81. PubMed ID: 22142663
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonates and breast cancer incidence and recurrence.
    Chlebowski RT, Col N.
    Breast Dis; 2011 Dec 20; 33(2):93-101. PubMed ID: 22142660
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D.
    Oncologist; 2006 Dec 20; 11(7):841-8. PubMed ID: 16880243
    [Abstract] [Full Text] [Related]

  • 17. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL.
    J Exp Clin Cancer Res; 2007 Sep 20; 26(3):307-12. PubMed ID: 17987788
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonates in lung cancer: more than a palliative therapy?
    Jahanzeb M, Hirsh V.
    Semin Oncol; 2010 Jun 20; 37 Suppl 1():S45-52. PubMed ID: 20682372
    [Abstract] [Full Text] [Related]

  • 19. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P, Bundred N.
    Semin Oncol; 2007 Dec 20; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [Abstract] [Full Text] [Related]

  • 20. Optimal management of metastatic bone disease.
    Major P.
    Eur J Oncol Nurs; 2007 Dec 20; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.